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E-mail address: anamikadhyani2009@gmail.com (ANKHD1 is a multiple ankyrin repeat containing protein, highly expressed in cancers, such as acute
leukemia. The present study was undertaken to determine the expression and functional signiﬁ-
cance of ANKHD1 in human Multiple Myeloma (MM). We found that ANKHD1 is highly expressed
in MM patient cells and cell lines. In vitro, lentiviral mediated ANKHD1-shRNA inhibited prolifera-
tion and delayed S to G2M cell cycle progression in glucocorticoid resistant (U266) and sensitive
(MM1S) MM cells. Further ANKHD1 silencing resulted in upregulation of cyclin dependent kinase
inhibitor p21 irrespective of the p53 status of the MM cell lines. These data suggest that ANKHD1
might have a role in MM cell proliferation and cell cycle progression by regulating expression of p21.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction ple ankyrin repeats and as single KH domain (ANKHD1). ANKHD1Multiple myeloma (MM) is a hematologic malignancy charac-
terized by the clonal proliferation of malignant plasma cells in
the bone marrow [1–3]. Development of MM is a multistep process
often associated with an increasing frequency of chromosomal
abnormalities and complex translocations that lead to overexpres-
sion of known and putative oncogenes [4,5]. Current therapies for
the disease include chemotherapy with or without stem cell trans-
plantation, glucocorticosteroids, thalidomide, the proteosome
inhibitor bortezomib, and combinations of these agents [6–8].
However, most of these treatments are not curative and therefore
development of new treatment approaches is required for effective
anti-cancer therapeutics. One major step towards the development
of cancer therapeutics is the functional characterization of actively
expressed genes which could possibly be targeted for cancer treat-
ment [9–13]. ANKHD1, Ankyrin repeat and KH domain containing
1, is one such gene overexpressed by primary acute leukemia cells
and leukemia cell lines [14]. ANKHD1 is located on human chromo-
some 5q31.3 as a single copy and encodes for a protein with multi-chemical Societies. Published by E
main containing 1
Hemotherapy Center, Univer-
78, Campinas, SP, Brazil. Fax:
A. Dhyani).is thought to function as a scaffolding protein associated with
abnormal phenotype of leukemia cells. Earlier study reports asso-
ciation of this protein with SH2-containing protein–tyrosine phos-
phatase (SHP2) in human leukemia cell line K562 and prostate
cancer cell line LNCaP, suggesting it to be an adaptor protein re-
quired for leukemogenesis and development of cancer [14]. Till
date, little is known regarding ANKHD1 and hence, its role in the
development of cancer and cancer therapeutics warrants investiga-
tion [14].
Owing to the ubiquitous expression of ANKHD1 and probable
role in the development of cancer, we set out to investigate
ANKHD1 expression and role in MM. In this study, we report for
the ﬁrst time the functional role of ANKHD1 in the proliferation
of MM cells. We found that ANKHD1 promotes proliferation by
regulating the cell cycle progression by downregulating p21
expression.
2. Materials and methods
2.1. Primary cells and cell culture
Primary tumor cells from bone marrow aspirates of MM pa-
tients (n = 10) were puriﬁed by Ficoll Hypaque separation (GE
healthcare), followed by CD138+ microbead selection (Miltenyi
Biotech, Auburn, CA). Four of ten MM patients (40%) patients hadlsevier B.V. All rights reserved.
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immunoglobulin A myeloma type (IgA), two (20%) had light-chain
MM (kappa) and for one MM patient immunoglobulin type was not
available. CD138+ (plasma) cell purity was above 95% as deter-
mined by ﬂow cytometry. Puriﬁed plasma cells from bone marrow
mononuclear cells (n = 2) and tonsils (n = 4) of healthy donors were
used as controls. All healthy donors and patients provided in-
formed written consent and the study was approved by the ethics
committee of the University of Campinas.
Human myeloma cell lines MM1R, MM1S, RPMI 8226 and U266
were a kind gift from Prof. Lionel J. Coignet, Department of Cancer
Genetics, Roswell Park Cancer Institute, Buffalo, New York, USA.
MM cell lines were cultured in RPMI-1640 medium supplemented
with 10% heat inactivated Fetal calf serum (FCS), glutamine,
100 lg/ml Penicillin and 100 lg/ml Streptomycin. 293T cells for
viral transfection were grown in DMEM containing 10% FCS.
HT1080 cells used for viral titration were grown in complete
MEM medium. All cells were maintained at 5% CO2 and 37 C tem-
perature in CO2 incubator.
2.2. Quantitative Real Time-PCR (qRT-PCR)
Total RNA was extracted from cells using the TRIzol reagent,
according to the manufacturer’s instructions (Invitrogen, Carlsbad,
CA, USA). The reverse transcription reaction was performed using
RevertAid™ First Strand cDNA Synthesis Kit, according to the man-
ufacturer’s instructions (MBI Fermentas, St. Leon-Rot, Germany).
Expression of ANKHD1 mRNA was detected by Maxima Sybr green
qPCR master mix, according to the manufacturer’s instructions
(MBI Fermentas, St. Leon-Rot, Germany) in the ABI 7500 Sequence
Detection System (PE Applied-Biosystem) using speciﬁc primers:
forward 50-TGTCCGAGGTTGAATCATTTT-30, reverse 50-GTCCGAGG
TTGAATCATTTTTT-30; HPRT was used as endogenous control. The
forward and reverse primers for HPRTwere 50-GAACGTCTTGCTCGA
GATGTGA-30 and 50-TCCAGCAGGTCAGCAAAGAAT-3, respectively.
Relative levels of gene expression were quantiﬁed using the equa-
tion, 2DDCT [15]. A negative ‘no template control’ was included
for each primer pair. The dissociation protocol was carried out at
the end of each run to check for non-speciﬁc ampliﬁcation. Three
replicas were run on the same plate for each sample.
2.3. Western blot
MM cell lines were harvested when in exponential phase and
used for extraction of proteins. Brieﬂy, cells were lysed in ice-cold
buffer (100 mM Tris–HCl pH 7.5, 10 mM EDTA, 10% Triton X,
100 mM NaF and phosphatase and protease inhibitors). Protein
content of the extracts was determined by Bradford assay. Equal
amounts of total protein extracts were then subjected to SDS–
PAGE followed by Western blot analysis with the indicated anti-
bodies and ECL™ Western Blotting Analysis System (Amersham
Pharmacia Biotech, UK Ltd., Buckinghamshire, England) as de-
scribed [15]. Polyclonal antibodies against ANKHD1, actin, cdk2,
cdk4 and p27 were from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Monoclonal antibody against p21 and p53 were from Cell
Signaling Technologies (Cell Signaling, Danvers, MA, USA).
2.4. Laser confocal analysis
MM cell lines were ﬁxed in 4% (w/v) paraformaldehyde in PBS
(pH 7.4) for 30 min at 25 C and washed two times for 5 min each
with PBS containing 0.5% (w/v) glycine. The washed cells were al-
lowed to adhere on 0.01% (w/v) poly-L-lysine coated coverslips, per-
meabilized with 0.2% (v/v) Triton X-100 (5–10 min) and blocked
with 1% BSA in PBS for 30 min. Cells were incubated overnight at
4 C with primary antibody against ANKHD1 (1:200 dilution). Afterwashing, the slides were labelled with Alexa Fluor 633-conjugated
anti-goat antibody (Molecular Probes, Leiden, Netherlands) for 2 h.
Cells were then incubated with FITC-conjugated phalloidin
(Sigma–Aldrich, MO, USA) at room temperature and coverslips with
ProLong Gold antifade reagentwith DAPI (Molecular Probes, Leiden,
Netherlands) were applied. Positive immunoreactivity was visual-
ized by laser confocal scanning (Zeiss LM510). In the absence of pri-
mary antibodies, application of secondary antibodies (negative
controls) failed to produce any signiﬁcant staining.
2.5. Lentivrus production and transduction of MM cell lines
Two short hairpin RNAs (shRNAs) targeting ANKHD1 gene were
designed and cloned in lentivirus expressing vectors as per manu-
facturers protocol (BLOCK-iT™ Lentiviral RNAi system, Invitrogen).
The RNAi candidate target sequences for ANKHD1 were 50-
TGTCCGAGGTTGAATCATTTT-30 (ANKHD1 shRNA1) and 50-ATGCA-
CACTGCCTTAATGTT-30 (ANKHD1 shRNA2). shRNA expressing
viruses were produced in 293T cells according to standard proto-
cols. Lentiviral shRNA vector against LacZ gene supplied by Invitro-
gen was used as the negative control.
MM cell lines were transduced with lentiviral ANKHD1 shRNA
vectors or control vector (Control shRNA) in the presence of 4 lg/
ml polybrene (Sigma–Aldrich, St. Louis, MO, USA) at multiplicity of
infection (MOI) of 1 and centrifuged at 800g for 1 h. Transduced
cells were then subjected to blasticidin selection for 10–15 days.
Blasticidin resistant cells were expanded and analyzed for prolifera-
tion, apoptosis and cell cycle or lysed for Western blotting.
2.6. Methylthiazoletetrazolium (MTT) assay for cell proliferation
Control shRNA and ANKHD1 shRNA cells were serum-starved in
0.5% FBS for 12 h. A total of 5  104 cells per well were then plated
in a 96-well plate in RPMI 10% FBS and incubated in a CO2 incuba-
tor for 24, 48 and 72 h at 37 C. After incubation, 5 mg/ml solution
of MTT was added to the wells and incubated at 37 C for 4 h. The
reaction was interrupted by using 0.1 N HCl in anhydrous isopro-
panol. Cell growth was evaluated by measuring the absorbance
at 570 nm, using an automated plate reader. All conditions were
tested in six replicates.
2.7. Cell cycle analysis by ﬂow cytometry
Cells were ﬁxed in 70% ethanol, for at least 2 h at 4 C, and
stained with 20 lg/ml propidium iodide (PI) containing 10 lg/ml
RNase A for 30 min at room temperature. Fluorescence cell analysis
was performed with a FACSCalibur (Becton–Dickinson, CA, USA).
Resulting DNA distributions were analyzed by Modiﬁt (Verify Soft-
ware House Inc., Topsham, ME, USA) for the proportions of cells in
the phases of the cell cycle.
2.8. Assessment of apoptosis by Annexin-V and PI staining
Control shRNA and ANKHD1 shRNA cells were seeded on 12-
well plates for 48 h. Cells were then harvested at 24 and 48 h,
washed twice with ice cold PBS and resuspended in binding buffer
containing 1 lg/ml PI and 1 lg/ml FITC labeled Annexin-V. All
specimens were analyzed on a FACS Calibur after incubation for
15 min at room temperature in a light-protected area. Ten thou-
sand events were acquired for each sample.
2.9. Statistical analysis
Statistical analysis was performed using GraphPad Instat 5
(Graph-Pad Software, Inc., San. Diego, CA, USA). For comparisons,
an appropriate Student’s t-test or Mann–Whitney test was used.
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experiments were repeated at least three times.
3. Results
3.1. ANKHD1 expression and localization
We used qRT-PCR to evaluate the expression of ANKHD1 in plas-
ma cells from MM patients and compared with that from healthy
donors. We found that plasma cells from MM patients had higher
expression of ANKHD1 when compared with plasma cells from
healthy donors (⁄P = 0.004) (Fig. 1a).
We also analyzed the expression of ANKHD1 mRNA in four MM
cell lines namely MM1R, MM1S, RPMI 8226 and U266. qRT-PCR
showed abundant expression of ANKHD1 mRNA in MM1S and
MM1R cell lines followed by RPMI 8226 and U266 cell lines
(Fig. 1b). In all four cell lines the expression was higher (2–5-fold)
than the positive control (K562). These ﬁndings were further cor-
roborated by Western blot analysis of ANKHD1 expression in these
cell lines, standardized to actin expression (Fig. 2a), which showed
high levels of ANKHD1 expression in MM1S and MM1R cell lines,
markedly lower levels in U266 cells. However RPMI 8226 that had
lower mRNA expression as compared to MM1S and MM1R cells,
showed the highest expression in Western blot. The expression of
ANKHD1 was characterized with a thick band of approximately
270 kDa in the immunoblot of MM cells, and expression of ANKHD1
in K562 was used as a positive control, as previously described.
Laser confocal analysis of all four MM cell lines studied showed
that ANKHD1 is predominantly located in the cytoplasm (Fig. 2b).Fig. 1. ANKHD1 expression in MM patient’s cells and cell lines. (A) qRT-PCR analysis of
Whitney test) in plasma cells derived fromMM patients as compared to healthy donors. H
MM1S, MM1R and RPMI 8266. A leukemia cell line K562 was taken as positive control. In
positive control (K562).3.2. Speciﬁc inhibition of ANKHD1 mRNA and protein expression by
ANKHD1 speciﬁc shRNA
To understand the signiﬁcance of ANKHD1 upregulation in MM
patients and cell lines, we used lentivirus vectors expressing
ANKHD1 speciﬁc shRNA for gene silencing. MM cell line, U266
was transduced with ANKHD1 shRNA1 and 2, separately. Degree
of knockdown in ANKHD1 expression was determined by qRT-
PCR analysis and Western blot. As shown in Fig. 3a and 3b, both
ANKHD1 speciﬁc shRNAs substantially decreased (⁄P < 0.05)
ANKHD1 mRNA and protein expression in U266 cells. However of
the two, ANKHD1 shRNA1 showed higher efﬁciency with 70%
and 80% inhibition in endogenous ANKHD1 mRNA and protein as
compared to 45% and 70% in case of ANKHD1 shRNA2 (Fig 3a
and b). MM1S transduced with ANKHD1 shRNA1 also showed sig-
niﬁcant (⁄P < 0.05) downregulation of ANKHD1 expression with
44% and 50% inhibition of endogenous ANKHD1mRNA and protein,
respectively. The effect of ANKHD1 silencing was speciﬁc, as cells
transduced with control shRNA (Lac Z gene) failed to knockdown
ANKHD1 expression (Fig. 3). Also, there was no signiﬁcant differ-
ence in ANKHD1 expression between untransduced and negative
control shRNA vector transduced cells (data not shown).
3.3. Effect of ANKHD1 knockdown on proliferation and apoptosis
To determine whether silencing ANKHD1 by shRNA had an
inhibitory effect on MM cells growth, cell proliferation was deter-
mined by MTT assay. Fig. 4 shows that inhibition of ANKHD1
expression by shRNA suppressed proliferation of MM cells.plasma cells. ANKHD1mRNA expression was signiﬁcantly higher (⁄P = 0.004, Mann–
orizontal lines represent median values. (B) qRT-PCR analysis of MM cell lines U266,
creased ANKHD1 expression was observed in all four MM cell lines as compared to
Fig. 2. ANKHD1 protein expression and localization in MM cell lines. (A) Western blot analysis. Equal amount (200 lg) of total protein extract was loaded for each cell line
and blotted with antibodies against ANKHD1 (270 kDa) and Actin (42 kDa), as control for equal sample loading. K562, a leukemia cell line, was taken as positive control.
Graph below shows quantiﬁcation of blots performed by using ImageJ software. (B) Laser confocal analysis was performed for localization of ANKHD1 in cells. MM cell lines
were ﬁxed and permeabilized and ANKHD1 was visualized by Alexa Fluor 633 anti-goat antibody (red ﬂourescence). FITC-conjugated phalloidin was used for Actin (green
ﬂuorescence) and DAPI for nuclei (blue ﬂuorescence). Positive immunoreactivity was visualized by laser confocal scanning (Zeiss LM510). In the absence of primary
antibodies, application of secondary antibodies (negative controls) failed to produce any signiﬁcant staining (data not shown). ANKHD1 is predominantly located in
cytoplasm of all four MM cell lines.
Fig. 3. Inhibition of ANKHD1 expression by speciﬁc shRNA. (A) Quantitative expression of ANKHD1 mRNA in ANKHD1 inhibited (ANKHD1 shRNA1, 2 or both) and control
(control shRNA) cells. Lentivirus-mediated ANKHD1 shRNA effectively silenced ANKHD1 in MM cell lines (U266 & MM1S), ⁄P < 0.05, Student’s t-test. Both the ANKHD1 speciﬁc
shRNAs (ANKHD1 shRNA1 and ANKHD1 shRNA2) effectively inhibited ANKHD1 mRNA expression in U266 cells. mRNA expression levels were normalized by HPRT as
endogenous control. Results were analyzed using 2DDCT. Experiments were performed in triplicates. (B) Western blot analysis of non-transduced, control shRNA and
ANKHD1 shRNA total cell extracts (U266 & MM1S). The membranes were blotted with antibodies against ANKHD1 or Actin (as a control for equal sample loading), and
developed with the ECL Western blotting analysis system.
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(MM1S) in ANKHD1 shRNA1 knockdown cells when compared
with control cells (⁄P < 0.05) at 48 h after incubation. Signiﬁcant
inhibition of proliferation was also observed in U266 cells trans-
duced with ANKHD1 shRNA2. There was signiﬁcant difference(⁄P < 0.05) in proliferation between control and ANKHD1 knock-
down MM cells at all three time points studied (Supplementary
Fig. 1).
We further evaluated the effect of inhibiting ANKHD1 expres-
sion by shRNA on apoptosis in MM cells. However, annexin-V anal-
Fig. 4. Effect of inhibition of ANKHD1 expression on MM cell proliferation and Apoptosis. (A) Cell proliferation was determined byMTT assay. ANKHD1 silencing inhibited cell
proliferation in both the cell lines. Both shRNAs (ANKHD1 shRNA1 and ANKHD1 shRNA2) were substantially able to inhibit proliferation in U266 cells. Results are shown as
mean ± SD of six replicates and it is representative of 3 independent experiments (⁄P < 0.05, Student’s t-test). (B) Inhibition of ANKHD1 expression did not induce apoptosis in
MM cell lines. Apoptosis in cells was determined by Annexin-V and PI staining.
A. Dhyani et al. / FEBS Letters 586 (2012) 4311–4318 4315ysis showed no signiﬁcant increase in apoptosis of cells transduced
with either of ANKHD1 shRNAs (Fig. 4b). This, therefore, indicates
that knockdown of ANKHD1 expression by shRNAs is not signiﬁ-
cantly effective in inducing apoptosis in MM1S and U266 cells.
Similar effects on proliferation and apoptosis, observed after
ANKHD1 silencing with both the shRNAs, implies that the effects
on cell functions are the result of RNAi-mediated silencing of the
targeted gene rather than off-target effects. Since ANKHD1 shRNA1
showed better efﬁciency we chose to carry out the subsequent
experiments with ANKHD1 shRNA1.
3.4. ANKHD1 silencing arrest cells in S phase of cell cycle
Cell cycle changes on inhibition of ANKHD1 was analyzed by
ﬂow cytometry. Separation of cells in G0/G1, S phase and G2/M
was based on linear ﬂuorescence intensity after staining with pro-
pium iodide. Cell cycle analysis showed signiﬁcant percentage in-
crease of cells in S phase when MM cells were transduced with
ANKHD1 shRNA (with not much difference to the proportion of
G2 cells) as compared to controls, ⁄P < 0.05 (Fig. 5a). We also ob-
served a concomitant decrease in the percentage of cells in G1
phase. Therefore ANKHD1 silencing caused accumulation of cells
in the S phase of the cycle.
3.5. Analysis of genes relevant to cell cycle progression and
proliferation
To address the mechanism of the antiproliferative effect of
ANKHD1 silencing, we examined the effect of ANKHD1 knockdown
on the expression of cell cycle and proliferation related genes,
including Cyclin dependent kinase inhibitors-p21 (CDKN1A) and
p27 (CDKN1B), Cyclins–cyclin A2 (CCNA2), cyclin B1 (CCNB1)
and cyclin E1 (CCNE1), Cyclin dependent kinases-CDK2 and CDK4
and Tumour suppressor protein p53 (TP53). Following theinhibition of ANKHD1 in U266, mRNA levels of CDKN1B, CCNB1and
CCNE1 were reduced by 42.2%, 23.1% and 30% compared to control,
respectively (Fig. 5b, above panel). Similarly on downregulation of
ANKHD1 in MM1S cells, mRNA levels for CDKN1B, CCNB1 and
CCNE1 were reduced by 42.3%, 23.2% and 18%, respectively
(Fig. 5b, below panel). On the other hand, CDKN1A was highly
upregulated in both U266 (>100%) and MM1S (52%) cell lines on
downregulation of ANKHD1 (Fig. 5b). No signiﬁcant changes in
CCNA2, CDK2 and CDK4 were observed on ANKHD1 silencing of
both U266 and MM1S cells at mRNA levels.
At protein levels as determined by western blot, the two cell
lines differed in levels of cyclin A protein with increase in U266
but a decrease in MM1S cells (Fig. 5c). However in contrast to
qRT-PCR results where there was no signiﬁcant difference in
CDK2 and CDK4, there was a decrease in cdk2 and cdk4 at protein
levels in both cell lines with almost complete inhibition in U266
cells (Fig. 5c). On the other hand in correlation with mRNA levels,
the level of p27 protein was reduced and p21 expression increased
in both cells with ANKHD1 silencing.
The two cell lines however showed difference in TP53 mRNA
expressions being up regulated in MM1S (50% increase), but down
regulated in U266 (52% decrease) cells with ANKHD1 inhibition
(Fig. 5b). These results correlated well with p53 protein levels as
determined by Western blot (Fig. 5c).
4. Discussion
ANKHD1 is reported to be highly expressed in leukemia cell
lines and is suspected to have a role in cancer development [14].
We investigated the expression of ANKHD1 in MM and the effect
of ANKHD1-targeted lentiviral shRNA on cell proliferation, apopto-
sis and cell cycle in MM cell lines U266 (glucocorticoid resistant)
and MM1S (glucocorticoid sensitive) [16]. In this study, the
expression of ANKHD1 in MM patients and cell lines was analyzed
Fig. 5. Effect of inhibition of ANKHD1 expression in cell cycle progression. (A) Cell cycle analysis. ANKHD1 inhibition caused accumulation of cells in S phase, as determined
by ﬂow cytometry. Results are represented as percentage of cell population in G1, S, and G2/M phases of the cell cycle. There was signiﬁcant increase (⁄P < 0.05, Student’s t-
test) in S phase cells with concomitant decrease in G1 phase cells in both cell lines U266 cells (left) and MM1S cells(right). Results are representative of 3 independent
experiments. (B) qRT-PCR-analyisis of cell cycle regulatory genes. ANKHD1 silencing affected expression of cell cycle related genes. CCNB1, CCNE1 and CDKN1B were
signiﬁcantly reduced (⁄P < 0.05) whereas CDKN1A was highly upregulated (⁄P < 0.05, Student’s t-test) in both MM cell lines U266 cells (above) and MM1S cells (below). There
was no signiﬁcant difference in CCNA2, CDK2 and CDK4. TP53 was upregulated in MM1S but downregulated in U266 cells. (C) Western blot analysis of cell cycle regulatory
proteins cyclin A, cdk2, cdk4, p27, p21 and p53 in control and ANKHD1 silenced U266 and MM1S cells. p21 was highly expressed in both the cell lines. Actin was used as
endogenous control.
4316 A. Dhyani et al. / FEBS Letters 586 (2012) 4311–4318by qRT-PCR. The results demonstrated that ANKHD1 was overex-
pressed in MM patients and cell lines. Although the number of pa-
tient samples studied were limited (n = 10), all of them showed
increased expression of ANKHD1 mRNA as compared to negative
controls. Furthermore, qRT-PCR results were corroborated with
western blot analysis that conﬁrmed overexpression of ANKHD1
in MM cell lines.
ANKHD1 overexpression suggests a potential role of this protein
in the MM pathophysiology. Previous studies with acute leukemia
patients and cell lines showed that ANKHD1 is associated with
SHP2, which had a possible role in cell proliferation and apoptosis
[14]. In the present study we sought to elucidate ANKHD1 role in
proliferation and apoptosis by inhibiting its expression in glucocor-
ticoid resistant U266 and sensitive MM1S cell lines. We used
lentiviral vector delivering shRNA speciﬁc to human ANKHD1 gene.One major problem of using shRNAs in experimentation is the pos-
sibility of off-target effects. Hence to conﬁrm the speciﬁcity of
RNAi results, we used two shRNAs targeting two different regions
on ANKHD1 gene. In addition we used shRNA targeting LacZ gene
(irrelevant gene) as negative control.Both the shRNAs used were
able to knockdown ANKHD1 expression signiﬁcantly (⁄P < 0.05)
at both mRNA and protein levels. Similar results were obtained
on proliferation, apoptosis and cell cycle analysis with both shR-
NAs. However transduction efﬁciency and effects of knockdown
of ANKHD1 expression was higher in cells transduced with
ANKHD1 shRNA1 and therefore ANKHD1 shRNA1 was chosen for
subsequent use in other myeloma cell line MM1S. Downregulation
of ANKHD1 expression was validated by qRT-PCR and western blot
following lentiviral transduction and selection and was signiﬁ-
cantly downregulated at both mRNA and protein levels in both cell
A. Dhyani et al. / FEBS Letters 586 (2012) 4311–4318 4317lines used (⁄P < 0.05). MTT assay was used to evaluate cell prolifer-
ation and revealed a signiﬁcant decrease in proliferation of cells
transduced with lentiviral ANKHD1 shRNA compared to control
shRNA (⁄P < 0.05) in both U266 and MM1S cell lines.
Following the downregulation of ANKHD1, cell growth was
inhibited, whereas there was no induction of cell apoptosis.
Changes in cell proliferation are usually associated with modula-
tion in the cell cycle [17,18]. Hence in order to explore the poten-
tial mechanism underlying the action of ANKHD1 expression in
regulating cell proliferation, cell cycles were characterized by FACS
analysis. We observed signiﬁcant increase in S phase cells after
transduction with lentiviral ANKHD1 shRNA as compared to cells
tranduced with control shRNA. There was a concomitant decrease
in G1 phase cells with no signiﬁcant changes in the percentage of
G2M phase cells. These ﬁndings suggest a role of ANKHD1 in cell
cycle progression and probably, the delay in progression from S
to G2/M or arrest in S phase was the reason for the antiproliferative
effect of ANKHD1 suppression in myeloma cells. Having observed
the accumulation of cells in S phase in ANKHD1 silenced cells,
we hypothesized that ANKHD1 downregulation might change the
expression of cell cycle genes. We examined by qRT-PCR analysis,
the levels of expression of several cell cycle related genes, to fur-
ther characterize the effect of ANKHD1 downregulation. We found
that expression of CDKN1B (p27), a negative regulator of cell cycle
and inhibitor of G1 phase cyclin/cdk activity [19,20], was downreg-
ulated on ANKHD1 inhibition. Hence, the progression from G1 to S
was not inhibited and there was a decrease in G1 phase cells. Con-
trarily, p21 (CDKN1A) that plays a major role in S phase progression
was highly upregulated at both mRNA and protein levels, suggest-
ing that the perturbation in S phase progression was due to the
negative regulation of cell cycle due to inhibition by p21 [21–23].
Furthermore, downregulation of ANKHD1 decreased, cyclin B and
cyclin E, G1 phase and G2 phase proteins, whereas there was no
signiﬁcant change in cyclin A which is the S phase protein [24].
At protein levels, expression of cdk2, cdk4, p27 (CDKN1B) was
decreased in both the cell lines with almost complete inhibition
of expression in U266 cells. On the other hand there was an in-
crease in cyclin A in U266 cells but a decrease in MM1S cells. Thus
the effects of ANKHD1 downregulation on the expression of cyclin
A appears to vary among cell systems. The observed decrease in cy-
clin A in MM1S cells was consistent with the observed delay in cell
cycle progression as cyclin A regulates S/G2 progression but its
upregulation in U266 could not be explained requiring further
investigation. The probable reason however, for inhibition of cell
cycle progression in U266 despite the high expression of cyclin A
could be attributed to the decrease of cdk2 total protein. Cdk2 is
cyclin dependent kinase that binds to cyclin A and whose activity
is required for progression through S phase [25,26]. In absence of
cdk2, cyclin A alone cannot lead S to G2 progression. Decrease in
cdk2 protein may be correlated to decrease in cyclin/cdk2 activity
due to upregulation of p21 that regulates cell cycle progression,
leading to delay in S phase progression [26,27].
We also analyzed expression of the tumour suppressor gene,
TP53, which is a potent transcriptional regulator of p21 and found
that TP53 was upregulated in MM1S but downregulated in U266
cells on downregulation of ANKHD1. The reason for this difference
may be due to the fact that p53 is wild type in MM1S but mutated
in U266 cell line [28]. Based on this ﬁnding, we can suggest that
inhibition of ANKHD1 in myeloma cell growth is independent of
p53 status of cells and the arrest of S phase might be mainly due
to upregulation of p21, induced by ANKHD1 inhibition [29–31].
However, exactly how ANKHD1 inhibition leads to upregulation
of p21 causing accumulation of cells in the S phase is not yet clear
and requires further investigation.
In conclusion, the present study demonstrates that ANKHD1 is
highly expressed in both MM patients and cell lines. Furtherknockdown of ANKHD1 using shRNA potently inhibits proliferation
and promotes cell cycle arrest without affecting rate of apoptosis in
both glucocorticoid resistant as well as sensitive multiple myeloma
cells. ANKHD1 overexpression may be associated with cell cycle
progression via downregulation of p21, independent of p53 in MM
cells. Further investigation of the functional role of ANKHD1 may
lead to a better understandingof themolecularmechanismofmulti-
ple myeloma. Also, studies with combination of drugs that induce
apoptosis and suppression of ANKHD1 may be an effective strategy
for treatment of myeloma, and therefore needed to be explored.
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